Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
- 1 November 1988
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 26 (5) , 601-603
- https://doi.org/10.1111/j.1365-2125.1988.tb05301.x
Abstract
Debrisoquine hydroxylation polymorphism was studied in 155 Finns and 70 Lapps. The frequency of the poor metabolizer phenotype was 3.2% among Finns (95% confidence interval 0.4‐6.0%) and 8.6% among Lapps (95% confidence interval 2.0‐15.1%).This publication has 13 references indexed in Scilit:
- Confidence intervals rather than P values: estimation rather than hypothesis testing.BMJ, 1986
- Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populationsClinical Pharmacology & Therapeutics, 1985
- A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquinClinical Pharmacology & Therapeutics, 1985
- The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.Journal of Medical Genetics, 1983
- The genetic control of drug oxidation in the liver.1983
- The Upjohn Award Lecture 1981/La Conférence Upjohn 1981: The metabolism of xenobiotics in different populationsCanadian Journal of Physiology and Pharmacology, 1982
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- Clinical Pharmacokinetics of IsoniazidClinical Pharmacokinetics, 1979
- Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detectionJournal of Chromatography A, 1977
- Demography of the Skolt Lapps in Northern Finland.1971